HCP
ABBV icon

Hexagon Capital Partners’s AbbVie ABBV Stock Holding History

Hexagon Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.09M Buy
8,314
+1,289
+18% +$277K 0.29% 34
2026
Q1 		$1.53M Buy
+7,025
New +$1.56M 0.22% 44
2025
Q2 		– Sell
-7,651
Closed -$1.6M – 80
2025
Q1 		$1.6M Sell
7,651
-324
-4% -$63K 0.3% 30
2024
Q4 		$1.42M Buy
7,975
+553
+7% +$102K 0.26% 33
2024
Q3 		$1.47M Sell
7,422
-409
-5% -$76.3K 0.29% 26
2024
Q2 		$1.34M Sell
7,831
-549
-7% -$90.9K 0.29% 27
2024
Q1 		$1.53M Buy
8,380
+636
+8% +$110K 0.34% 20
2023
Q4 		$1.2M Sell
7,744
-386
-5% -$56.3K 0.29% 26
2023
Q3 		$1.21M Buy
8,130
+981
+14% +$144K 0.32% 26
2023
Q2 		$963K Sell
7,149
-682
-9% -$100K 0.25% 36
2023
Q1 		$1.25M Buy
7,831
+747
+11% +$114K 0.35% 30
2022
Q4 		$1.14M Sell
7,084
-755
-10% -$116K 0.33% 31
2022
Q3 		$1.05M Buy
7,839
+3,911
+100% +$561K 0.31% 33
2022
Q2 		$602K Buy
3,928
+531
+16% +$81.1K 0.18% 67
2022
Q1 		$551K Sell
3,397
-238
-7% -$34.6K 0.15% 87
2021
Q4 		$492K Sell
3,635
-20
-0.5% -$2.36K 0.13% 92
2021
Q3 		$394K Buy
3,655
+513
+16% +$58.6K 0.11% 96
2021
Q2 		$354K Buy
3,142
+9
+0.3% +$1.01K 0.1% 106
2021
Q1 		$339K Buy
3,133
+95
+3% +$10.2K 0.09% 100
2020
Q4 		$325K Buy
3,038
+201
+7% +$19.3K 0.1% 90
2020
Q3 		$250K Buy
+2,837
New +$267K 0.08% 98

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Hexagon Capital Partners's ABBV Position: Q2 2026 in Review

Hexagon Capital Partners increased its AbbVie (ABBV) stake by 18% in Q2 2026, buying an estimated $277K and bringing the position to 8,314 shares worth $2.09M. The position accounts for 0.29% of the portfolio, ranked #34.

Hexagon Capital Partners first reported a position in ABBV in Q3 2020 and has held it in 21 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Hexagon Capital Partners held 8,314 shares of AbbVie worth $2.09M as of Q2 2026.
  • Hexagon Capital Partners bought 1,289 AbbVie shares in Q2 2026, an estimated $277K.
  • AbbVie made up 0.29% of Hexagon Capital Partners's portfolio in Q2 2026, its #34 holding.
  • Hexagon Capital Partners first reported a position in AbbVie in Q3 2020 and has held it in 21 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Hexagon Capital Partners's 13F filing for Q2 2026, filed 7 Aug 2026.